Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G Merger Talks Bring Pharmaceutical-As-Consumer-Brand Idea To Fore

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble's aborted merger discussions with Warner-Lambert and American Home Products may herald the next phase in the evolution of consumer-focused pharmaceutical marketing.

You may also be interested in...

Miza Pharmaceuticals USA

Purchase of NutraMax's Optopics Laboratories ophthalmics division gives the Burlington, Mass.-based contract manufacturing and packaging firm an OTC product base that includes branded and private label eye drops, artificial tears, contact lens solution and cleansers, and industrial eye wash, along with eight Rx products. The deal closed Dec. 31 for an undisclosed sum; Optopics' FY 1998 sales totaled approximately $12 mil. Under the terms of the transaction, Miza acquired the division's 34,000 sq. ft. manufacturing and office facility in Fairton, N.J. The company anticipates no reductions in Optopics' 86-employee work force

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts